Cargando…

Three cachexia phenotypes and the impact of fat‐only loss on survival in FOLFIRINOX therapy for pancreatic cancer

BACKGROUND: By the traditional definition of unintended weight loss, cachexia develops in ~80% of patients with pancreatic ductal adenocarcinoma (PDAC). Here, we measure the longitudinal body composition changes in patients with advanced PDAC undergoing 5‐fluorouracil, leucovorin, irinotecan, and ox...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kays, Joshua K., Shahda, Safi, Stanley, Melissa, Bell, Teresa M., O'Neill, Bert H., Kohli, Marc D., Couch, Marion E., Koniaris, Leonidas G., Zimmers, Teresa A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2018
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6104116/ https://www.ncbi.nlm.nih.gov/pubmed/29978562 http://dx.doi.org/10.1002/jcsm.12307

Ejemplares similares

Identification of Potential Serum Protein Biomarkers and Pathways for Pancreatic Cancer Cachexia Using an Aptamer-Based Discovery Platform
por: Narasimhan, Ashok, et al.
Publicado: (2020)

Sex specificity of pancreatic cancer cachexia phenotypes, mechanisms, and treatment in mice and humans: role of Activin
por: Zhong, Xiaoling, et al.
Publicado: (2022)

The systemic activin response to pancreatic cancer: implications for effective cancer cachexia therapy
por: Zhong, Xiaoling, et al.
Publicado: (2019)

Profiling of Adipose and Skeletal Muscle in Human Pancreatic Cancer Cachexia Reveals Distinct Gene Profiles with Convergent Pathways
por: Narasimhan, Ashok, et al.
Publicado: (2021)

Differential Bone Loss in Mouse Models of Colon Cancer Cachexia
por: Bonetto, Andrea, et al.
Publicado: (2017)

The MEK-Inhibitor Selumetinib Attenuates Tumor Growth and Reduces IL-6 Expression but Does Not Protect against Muscle Wasting in Lewis Lung Cancer Cachexia
por: Au, Ernie D., et al.
Publicado: (2017)

The impact of inflammation and acute phase activation in cancer cachexia
por: Robinson, Tyler P., et al.
Publicado: (2023)

STAT3 Activation in Skeletal Muscle Links Muscle Wasting and the Acute Phase Response in Cancer Cachexia
por: Bonetto, Andrea, et al.
Publicado: (2011)

Modelling survival
por: Zimmers, Teresa A, et al.
Publicado: (2019)

Tumor-derived IL-6 and trans-signaling among tumor, fat, and muscle mediate pancreatic cancer cachexia
por: Rupert, Joseph E., et al.
Publicado: (2021)

Sex Differences in Cancer Cachexia
por: Zhong, Xiaoling, et al.
Publicado: (2020)

The Combination of Low Skeletal Muscle Mass and High Tumor Interleukin-6 Associates with Decreased Survival in Clear Cell Renal Cell Carcinoma
por: Kays, Joshua K., et al.
Publicado: (2020)

Inflammation, organomegaly, and muscle wasting despite hyperphagia in a mouse model of burn cachexia
por: Pedroso, Felipe E., et al.
Publicado: (2012)

An invitation to the 2nd Cancer Cachexia Conference, Montréal, Canada
por: Guttridge, Denis, et al.
Publicado: (2014)

Pathological Responses of Cardiac Mitochondria to Burn Trauma
por: Wang, Meijing, et al.
Publicado: (2020)

Editorial: Metabolic Adaptation of Muscle Tissue in Diseases Associated With Cachexia
por: Cirillo, Federica, et al.
Publicado: (2022)

Sarcopenia is a Significant Predictor of Mortality After Abdominal Aortic Aneurysm Repair
por: Kays, Joshua K., et al.
Publicado: (2018)

Ethical Implications of Modifying Lethal Injection Protocols
por: Koniaris, Leonidas G, et al.
Publicado: (2008)

Growth of ovarian cancer xenografts causes loss of muscle and bone mass: a new model for the study of cancer cachexia
por: Pin, Fabrizio, et al.
Publicado: (2018)

Do Plastic Surgery Programs with Integrated Residencies or Subspecialty Fellowships Have Increased Academic Productivity?
por: Duquette, Stephen P., et al.
Publicado: (2016)

Determining the Drivers of Academic Success in Surgery: An Analysis of 3,850 Faculty
por: Valsangkar, Nakul P., et al.
Publicado: (2015)

Lethal Injection for Execution: Chemical Asphyxiation?
por: Zimmers, Teresa A, et al.
Publicado: (2007)

Increase in Muscle Mitochondrial Biogenesis Does Not Prevent Muscle Loss but Increased Tumor Size in a Mouse Model of Acute Cancer-Induced Cachexia
por: Wang, Xiao, et al.
Publicado: (2012)

Chemotherapy-related cachexia is associated with mitochondrial depletion and the activation of ERK1/2 and p38 MAPKs
por: Barreto, Rafael, et al.
Publicado: (2016)

Vitamin D and VDR in cancer cachexia and muscle regeneration
por: Camperi, Andrea, et al.
Publicado: (2017)

Overall survival of patients with recurrent pancreatic cancer treated with systemic therapy: a retrospective study
por: Gbolahan, Olumide B., et al.
Publicado: (2019)

ACVR2B antagonism as a countermeasure to multi‐organ perturbations in metastatic colorectal cancer cachexia
por: Huot, Joshua R., et al.
Publicado: (2020)

Modified FOLFIRINOX for resected pancreatic cancer: Opportunities and challenges
por: Yang, Feng, et al.
Publicado: (2019)

Metabolic Biomarkers for the Early Detection of Cancer Cachexia
por: O’Connell, Thomas M., et al.
Publicado: (2021)

Adjuvant FOLFIRINOX in Patients with Resectable Pancreatic Cancer Is Effective but Rarely Feasible in Real Life: Is Neoadjuvant FOLFIRINOX a Better Option?
por: Maman, Yossi, et al.
Publicado: (2023)

Novel models for prediction of benefit and toxicity with FOLFIRINOX treatment of pancreatic cancer using clinically available parameters
por: Schlick, Konstantin, et al.
Publicado: (2018)

Cachexia induced by cancer and chemotherapy yield distinct perturbations to energy metabolism
por: Pin, Fabrizio, et al.
Publicado: (2019)

Pancreatic cancer and FOLFIRINOX: a new era and new questions
por: Marsh, Robert De W, et al.
Publicado: (2015)

Folfirinox in elderly patients with pancreatic or colorectal cancer-tolerance and efficacy
por: Guion-Dusserre, Jean-Florian, et al.
Publicado: (2016)

An assessment of the benefit-risk balance of FOLFIRINOX in metastatic pancreatic adenocarcinoma
por: Péron, Julien, et al.
Publicado: (2016)

FOLFIRINOX in borderline resectable and locally advanced unresectable pancreatic adenocarcinoma
por: Yoo, Changhoon, et al.
Publicado: (2020)

Cancer of Unknown Primary With Presumptive Pancreatic Cancer Treated With FOLFIRINOX
por: Inoue, Naonori, et al.
Publicado: (2021)

The role of FOLFIRINOX in metastatic pancreatic cancer: a meta-analysis
por: Zhang, Beilei, et al.
Publicado: (2021)

Overcoming negative predictions of microRNA expressions to gemcitabine response with FOLFIRINOX in advanced pancreatic cancer patients
por: Schlick, Konstantin, et al.
Publicado: (2020)

Treatment with Soluble Activin Receptor Type IIB Alters Metabolic Response in Chemotherapy-Induced Cachexia
por: O’Connell, Thomas M., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_596auq581djb152hlc1e2qipa2